1 / 15

Protopic ® (tacrolimus) Ointment

Protopic ® (tacrolimus) Ointment. Fujisawa Healthcare, Inc. February 15, 2005. Amy Paller, MD Professor & Chair, Dermatology Professor of Pediatrics Feinberg School of Medicine Northwestern University. M. Joyce Rico, MD Senior Medical Director Fujisawa Healthcare, Inc.

marvel
Download Presentation

Protopic ® (tacrolimus) Ointment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Protopic® (tacrolimus) Ointment Fujisawa Healthcare, Inc. February 15, 2005 Amy Paller, MD Professor & Chair, Dermatology Professor of Pediatrics Feinberg School of Medicine Northwestern University M. Joyce Rico, MD Senior Medical Director Fujisawa Healthcare, Inc

  2. Atopic Dermatitis • Intensely itchy, painful relapsing inflammatory skin disease • Affects up to 20% of school age children • Serious impact on quality of life • Lack of sleep • Function at school, work • Social impairment

  3. Atopic Dermatitis • Higher rate of infections • Bacteria, herpes • Higher risk of asthma • Cutaneous T cell lymphoma (CTCL) is often misdiagnosed as atopic dermatitis

  4. Need For Treatment Options • Protopic and Elidel are the only non-steroidal topical options for AD treatment • Treatment options vary with different patient populations • Not every drug/treatment works for all patients • Some treatments may be contraindicated or not well tolerated

  5. Treatment Options in AD Mild Moderate Severe Topical Steroids Elidel Protopic Oral Steroids Light treatment Cyclosporine, mycophenolate

  6. Topical Calcineurin Inhibitors • Protopic and Elidel: • Differ in vehicle and indicated patient population • Protopic: moderate-severe AD • Elidel: mild-moderate AD • Similar safety profile in the same patient populations • Important therapeutic option

  7. M. Joyce Rico, MDSenior Medical DirectorFujisawa Healthcare, Inc

  8. Overview • Protopic is an important and effective treatment alternative for patients with moderate to severe AD • There is no evidence of systemic immune suppression or increased risk of malignancies

  9. Protopic Safety and Efficacy • Protopic is an important, safe and effective therapeutic option for patients with moderate-severe AD • Treatment options are limited • In extensive clinical trials (>19,000 patients treated, 7600 pediatric patients): • No increased risk of systemic infection • No increased risk of malignancy • No impairment of systemic immune response

  10. Minimal Systemic Exposure • Minimal absorption after topical application of Protopic • Most patients have blood levels < 0.5 ng/mL • Absolute bioavailability is approximately 0.5% • No systemic accumulation • When detected, blood levels are transient • Because there is minimal systemic absorption, the likelihood of systemic infection or malignancy is remote.

  11. ODS Post-marketing Analysis • Serious adverse events in patients <2 years • 10 reports • All except septicemia are in current labeling • Malignancy related reports • Globally, there have been 19 post-marketing malignancy related adverse events • A causal relationship has not been established

  12. Malignancy Risk Evaluation • Malignancies identified from transplant experience • Lymphoma (Post-transplant lymphoproliferative disease) • Non-Melanoma Skin Cancer (NMSC) • Malignancy rates in general US population: • Lymphoma 22 / 100,000 (SEER) • NMSC 533/100,000 (PHS) • Malignancies reported in 1.7M Protopic treated US patients • Lymphoma 11 ( including 6 CTCL) • NMSC 16 • There are no lymphomas or NMSC in patients <16 years There is no increased rate of malignancy for patients treated with Protopic compared with the expected rates in the population.

  13. Labeling Considerations • Protopic labeling contains appropriate precautions • Evidence does not indicate immune suppression or an increased risk of associated diseases • If changes to current labeling for this class are recommended: • Information should reflect current scientific knowledge • Information should balance risks and benefits

  14. Summary • AD is a serious, life-altering disease; treatment options are important • Topical calcineurin inhibitors are safe and effective treatments • Extensive clinical and post-marketing experience • No increased risk of systemic infection or malignancy • Fujisawa is committed to the safety of patients and appropriate communication with patients, parents and healthcare providers.

  15. External Consultants • Samuel Cohen, MD, PhD U of Nebraska Medical Center, Dept of Pathology & Microbiology • Michael Green, MD, MPH U of Pittsburgh, Dept of Pediatrics • Peter Heald, MD Yale University, Dept of Dermatology • Annette Stemhagen, DrPH, FISPE Covance Periapproval Services, Epidemiologist

More Related